氨磺必利与奥氮平治疗女性精神分裂症的对照研究  被引量:22

The Treatment of Female Schizophrenia Using Amisulpride and Olanzapine

在线阅读下载全文

作  者:吕振雷[1] 周振和[1] 张云彪[1] 

机构地区:[1]中国 江苏省无锡市精神卫生中心精神科, 214151

出  处:《中国健康心理学杂志》2014年第4期499-501,共3页China Journal of Health Psychology

摘  要:目的评价氨磺必利与奥氮平治疗女性精神分裂症的疗效和安全性。方法对符合CCMD-Ⅲ的女性精神分裂症诊断标准的80例患者,随机分为氨磺必利组和奥氮平组,各治疗8周。采用阳性和阴性症状量表(PANSS)和副反应量表(TESS)评定疗效及副反应。结果氨磺必利组显效率为75%,奥氮平组显效率为72.5%,两组有效率均为92.5%,差异无统计学意义;两组治疗前后各时点PANSS总分及各因子分比较差异均无统计学意义(t=0.08、0.82,0.34、0.32,P>0.05)。两组治疗中的不良反应发生率低、程度轻。结论氨磺必利与奥氮平治疗女性精神分裂症疗效相当,不良反应轻。两种药物均为疗效好、安全性高的抗精神病药。Objective To compare efficacy and safety of amisulpride and olanzapine in the treatment of female schizophrenia. Meth- ods 80 adult patients were recruited in the study. All the cases were diagnosed as female schizophrenia in accordance with the CCMD - Ⅲ diagnosis standard and randomized into two groups which were treated with amisulpride and olanzapine for 8 weeks. The Positive and Negative Syndrome Scale(PANSS) and Treatment Emergent Side effect Scale (TESS)were used to evaluate efficacy and adverse effects respectively before and at the ends of 2,4,8 weeks treatment. Results The effective rate in amisulpride group effiaccounted 75% , olanzapine group was 72.5% ,two groups of effectiveness was 92.5% ,there was no statistically significant difference( P 〉 0.05 ) ;There were no significant differences between both groups in each total scores of PANSS add each factor score at pre -treatment,2,4,8 weeks after treatment ( t = 0. 08 ,0. 82 ,0. 34 ,0. 32 ; P 〉 0.05 ). The rate of adverse reaction in the two groups was low, and mild. Conclusion Amisulpride and olanzapine have similar effectives in the treatment of female schizophrenia and few side effects. They are efficient and safe antipsychotic drugs in treatment schizophrenia.

关 键 词:精神病学 氨磺必利 奥氮平 女性精神分裂症 

分 类 号:B845.4[哲学宗教—心理学] R749.4[医药卫生—神经病学与精神病学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象